Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 371.70%
Price change 2019 → 2020: -99.89%
Price change 2020 → 2021: -92.73%
Price change 2021 → 2022: 0.00%
Price change 2022 → 2023: 150.00%
Price change 2023 → 2024: 0.00%
Price change 2024 → 2025: 140.00%
Price change 2025 → 2026: 983.33%
Price change 2026 (year to date): 983.33%
Financial growth
Revenue CAGR (8 years): 14.94%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.21
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio not available.
Correction (6 months)
Current correction: 0.00% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="AOBI" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by American Oriental Bioengineering, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2010 | 306 m | 14.1 m | 4.6 % | n/a |
| 2011 | 213 m | -68.5 m | -32.2 % | -30.5 % |
| 2012 | 145 m | -59.7 m | -41.1 % | -31.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 20/11/2026.
Accounts and financial health
Balance sheet and cash flow published by American Oriental Bioengineering, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 21/11/2026.
Valuation and competitors
American Oriental Bioengineering, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| American Oriental Bioengineering, Inc. | 949 | n/a | n/a |
| Cardax, Inc. CDXI | 80 | n/a | n/a |
| Nobilis Health Corp. NRTSF | 78 | n/a | n/a |
| Mymetics Corporation MYMX | 46 | n/a | n/a |
| NexImmune, Inc. NEXI | 139 | n/a | n/a |
| Cannabiz Mobile, Inc. LGBI | 505 | n/a | n/a |
| Sector 10, Inc. SECI | 31 | n/a | n/a |
| Poniard Pharmaceuticals, Inc. PARD | 150 | n/a | n/a |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 20/11/2026. Competitors: comparable companies named by the data provider.
Dividends and earnings
American Oriental Bioengineering, Inc.: dividend history, last distributions, stock splits and earnings releases.
No known dividend for this company.
Stock splits
| Date | Operation |
|---|---|
| 21/08/2014 | reverse split: 1 share for 501 |
| 03/04/2014 | reverse split: 1 share for 501 |
| 27/02/2012 | reverse split: 1 share for 2 |
Factual data: ex-dividend history and earnings calendar, as of 21/11/2026. A past dividend does not guarantee the next one.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in American Oriental Bioengineering, Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 21/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about American Oriental Bioengineering, Inc.
What is the American Oriental Bioengineering, Inc. share price?
Latest recorded price: 0.0130 USD on 20/11/2026, for a market cap of 949 USD.
What is the revenue of American Oriental Bioengineering, Inc.?
145 m USD for fiscal year 2012, with net income of -59.7 m USD (net margin -41.1 %).
Is American Oriental Bioengineering, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0287315032).
How many employees does American Oriental Bioengineering, Inc. have?
3,719 full-time employees according to the latest published profile.
Who runs American Oriental Bioengineering, Inc.?
Shujun Liu is the company's chief executive.